AbCellera Biologics Inc.
ABCLAbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Feb 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
ABCL Earnings Report
EPS Est: $-0.17 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How ABCL's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ABCL635 | Phase 2 | Vasomotor Symptoms Associated With Menopause | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AbCellera Biologics Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in AbCellera Biologics Inc.'s (ABCL) pipeline across Phase 2. Its lead program is ABCL635 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AbCellera Biologics Inc.'s next FDA catalyst?→
AbCellera Biologics Inc.'s (ABCL) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABCL biotech catalysts?→
Add ABCL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AbCellera Biologics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.